Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CORT with free AI briefings, catalyst countdowns, and dilution alerts.

CORT · CORCEPT THERAPEUTICS INC

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$662.3M Cash on Hand
CF+ Cash Runway
10.7% Short Interest
$142.6 Analyst Target (5)
Follow CORT by email Get an email when CORT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CORT, unsubscribe in one click. Privacy

💊 Upcoming FDA Decisions

PDUFA DateDrugIndicationTypePoAOptions-implied move
2026-12-17 Relacorilant Cushing's syndrome NDA 54% ±24% by Dec 18

Options-implied move = price of the at-the-money straddle for the first option expiry after the PDUFA date, as a share of the stock price (Yahoo Finance quotes, Nov 17). It prices every move until that expiry, not only the FDA decision.

PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →

📣 What CORT Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Mifepristone
FDA approved Feb 2012 · Korlym
Hypercortisolism Phase 4 · NCT05772169 Completed
Relacorilant (CORT125134)
FDA approved Mar 2026 · Lifyorli (Copackaged)
Metastatic Pancreatic Ductal Adenocarcinoma Phase 3 · NCT04329949 Terminated
Nab-paclitaxel Metastatic Pancreatic Ductal Adenocarcinoma Phase 3 · NCT04329949 Terminated
Nenocorilant Neoplasms Phase 1/2 · NCT07276373 Recruiting
Miricorilant (CORT118335) Antipsychotic-induced Weight Gain (AIWG) Phase 2 · NCT03818256 Completed
TPC Metastatic Breast Cancer Phase 2 · NCT06099769 Recruiting
Exicorilant Metastatic Castration-Resistant Prostate Cancer Phase 1/2 · NCT03437941 Terminated
Dazucorilant Amyotrophic Lateral Sclerosis Phase 2 · NCT05407324 Active not recruiting
[14C]-CORT113176 Healthy Phase 1 · NCT04990310 Completed
CORT113176 Lipid Capsule Formulation Healthy Adults Phase 1 · NCT04249323 Completed
CORT113176 Healthy Adults Phase 1 · NCT04994743 Completed
CORT125236 Healthy Phase 1 · NCT05003713 Completed
CORT125329 lipid capsule formulation Healthy Phase 1 · NCT04672512 Completed
Moxifloxacin Healthy Phase 1 · NCT04795479 Completed
Fluvoxamine Antipsychotic Induced Weight Gain Phase 1 · NCT05712265 Completed

Also used in these trials (approved or third-party drugs, not CORT's own candidates): Bevacizumab, Nivolumab, Gemcitabine Hydrochloride, Enzalutamide, Olanzapine, Pembrolizumab, Prednisone, Risperidone, Dabigatran Etexilate, Itraconazole.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CORT holds $662.3M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 15 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CORT files for a raise →

👥 Who Owns CORT

Insiders 10.4% Institutions (633 holders) 71.9% Public and other holders 17.7%
HolderTypeShares% of sharesAs of
BlackRock, Inc. Institution (13G, 5%+) 9,614,217 8.78% 2026-09-30
INGALLS & SNYDER LLC Institution (13G, 5%+) 7,263,466 6.64% 2025-12-31
G Leonard Jr Baker
Director · +12,500 options
Insider 5,550,196 5.07% 2026-03-17
Renaissance Technologies, LLC Institution (13F) 4,850,083 4.43% 2026-09-30
Vanguard Portfolio Management LLC Institution (13F) 4,777,065 4.36% 2026-09-30
Vanguard Capital Management LLC Institution (13F) 4,353,398 3.98% 2026-09-30
Parallel Advisors, LLC Institution (13F) 3,902,544 3.57% 2026-09-30
AQR Capital Management, LLC Institution (13F) 3,640,962 3.33% 2026-09-30
FMR, LLC Institution (13F) 3,488,722 3.19% 2026-09-30
State Street Corporation Institution (13F) 3,104,960 2.84% 2026-09-30
Joseph K Belanoff
Chief Executive Officer, Director · +460,000 options
Insider 2,865,489 2.62% 2026-05-29
Geode Capital Management, LLC Institution (13F) 2,335,372 2.13% 2026-09-30

Share count 109,443,109 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-10
filed 2026-11-13
Swisher Daniel N JR
Option exercise (M) 1,100 $14.08 1,100
2026-11-10
filed 2026-11-13
Swisher Daniel N JR
Option exercise (M) 400 $10.50 1,500
2026-11-10
filed 2026-11-13
Swisher Daniel N JR
Sale (S) 1,500 $74.07 0
2026-11-10
filed 2026-11-13
Swisher Daniel N JR
Option exercise (M) 1,100 – –
2026-11-10
filed 2026-11-13
Swisher Daniel N JR
Option exercise (M) 400 – –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-07-11 Relacorilant NDA +18.6% — —
2025-12-31 — NDA -11.6% -50.4% -47.3%
2025-12-30 relacorilant NDA +0% -12.1% -55.2%
2025-09-30 — NDA +20.6% -0.9% +7.1%

Browse all historical PDUFA outcomes →

Get the full CORT picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CORT and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.